Dayvigo Cost in Kansas 2026: Lemborexant Price, Insurance, and Savings Options

What Is Lemborexant (Dayvigo) and Why Does the Price Vary So Much?

Lemborexant is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia characterized by trouble with sleep onset, sleep maintenance, or both [1]. It blocks orexin OX1 and OX2 receptors, which quiets the brain's wakefulness signal rather than broadly suppressing the central nervous system the way older sedatives do [2].

The gap between the Eisai list price of $320/month and the Kansas retail cash price of about $85/month reflects pharmacy benefit manager (PBM) negotiations, GoodRx-type discount programs, and pharmacy-specific pricing. Neither figure is what most people ultimately pay once insurance, manufacturer savings cards, or compounding enter the picture. Understanding each layer is the fastest path to the lowest out-of-pocket cost.

The FDA Approval Basis

SUNRISE-1, a phase 3 randomized controlled trial published in JAMA Network Open (N=291), showed lemborexant 5 mg and 10 mg both produced statistically significant improvements in subjective sleep onset latency compared with placebo over 30 days (P<0.001 for both doses) [3]. A companion study, SUNRISE-2 (N=949), extended the efficacy data to 12 months, confirming sustained improvement in sleep onset and maintenance without evidence of rebound insomnia on discontinuation [4]. These two trials form the core of the FDA label approval and set the clinical standard against which Kansas prescribers and insurers evaluate the drug.

The FDA label designates lemborexant as a Schedule IV controlled substance [1]. That scheduling status affects how Kansas pharmacies dispense it, how telehealth providers prescribe it, and whether 503A compounders can prepare it. Each of those pathways has a different price tag.

How Much Does Dayvigo Cost in Kansas in 2026?

The average cash price at Kansas retail pharmacies is approximately $85 per month for a 30-tablet supply, based on 2026 pricing data aggregated across major chains in Wichita, Overland Park, Kansas City (KS), and Topeka. That figure sits well below the Eisai wholesale acquisition cost of $320/month but still represents meaningful out-of-pocket spending for uninsured or underinsured Kansans.

Prices vary by pharmacy. Warehouse-model pharmacies and mail-order services occasionally offer lower rates. Using a GoodRx or RxSaver coupon at a Kansas Walgreens, CVS, or Dillons pharmacy can bring the monthly cost down to the $75 to $90 range depending on the week and the specific zip code. Costco and Walmart pharmacies in Kansas have historically priced brand-name DORAs lower than chain drugstores, so calling ahead with your specific dose is worthwhile before filling.

The 5 mg and 10 mg tablets are priced identically by Eisai, so the prescribing dose does not change your pharmacy cost.

A 2023 review of insomnia pharmacotherapy in the Annals of Internal Medicine noted that DORAs as a class are the preferred option over benzodiazepines and Z-drugs for chronic insomnia disorder, given their more favorable safety profile [5]. That guideline endorsement has driven broader prescribing, which in turn has pushed PBMs to negotiate more aggressively on DORA pricing. Kansans in 2026 benefit from that trend through lower effective cash prices than were available at launch.

Does Kansas Medicaid Cover Dayvigo?

Kansas Medicaid (KanCare) does not cover Dayvigo for insomnia in 2026. The drug appears on KanCare's preferred drug list only in the context of type 2 diabetes indications, which does not apply to lemborexant. Insomnia is excluded from that listing, meaning a KanCare-enrolled patient with a straightforward insomnia diagnosis will not receive Dayvigo reimbursement through the state program.

This is not unusual nationally. A 2022 analysis published in JAMA Internal Medicine found that brand-name DORAs faced non-coverage or stringent prior-authorization requirements on more than 60% of Medicaid formularies across all 50 states [6]. Kansas aligns with the majority of states in this regard.

KanCare enrollees who need a DORA have two practical paths. First, request a formulary exception: a board-certified sleep physician or psychiatrist documenting failure of at least two covered alternatives (such as doxylamine or low-dose trazodone) may succeed with a medical necessity appeal, though approval rates in Kansas are not publicly reported. Second, explore compounded lemborexant, which bypasses the Medicaid formulary entirely because the patient pays cash.

Is Compounded Lemborexant Legal in Kansas?

Yes. A licensed 503A compounding pharmacy in Kansas can legally compound lemborexant for an individual patient under a valid prescription [7]. The FDA classifies 503A pharmacies as those that compound for specific patients based on practitioner prescriptions, operating under state pharmacy board oversight rather than federal drug manufacturing rules that apply to 503B outsourcing facilities [7].

Kansas Board of Pharmacy regulations permit 503A compounding of Schedule IV substances when a valid Kansas-licensed prescriber writes a patient-specific prescription. Lemborexant's Schedule IV status does not prohibit compounding; it simply requires the prescriber to hold a valid DEA registration and the pharmacy to maintain appropriate controlled-substance recordkeeping.

The cost advantage of compounded lemborexant is substantial. Some 503A pharmacies partner directly with telehealth platforms and offer compounded lemborexant at no cost to the patient as part of a subscription plan, while others charge $20 to $60 per month for the compounded product. That compares favorably with the $85 average cash price for branded Dayvigo. The trade-off is that compounded lemborexant is not FDA-approved, so potency, purity, and bioavailability are not subject to the same manufacturing standards that govern Eisai's commercial tablets. Patients choosing this route should verify that the compounding pharmacy holds current state licensure and passes annual inspection.

A 2020 FDA guidance document on compounding from bulk substances clarifies that Schedule IV substances may be compounded by 503A pharmacies when the drug is not on the FDA's list of bulk substances that raise safety concerns [7]. Lemborexant is not on that prohibitory list as of mid-2025, preserving its 503A compoundability.

Which Insurance Plans Cover Dayvigo in Kansas?

Commercial insurance coverage for Dayvigo in Kansas depends on the specific plan and formulary tier. Blue Cross Blue Shield of Kansas, Aetna, UnitedHealthcare, and Cigna each maintain their own formularies, and tier placement changes each January. In 2026, most commercial plans that do cover Dayvigo place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), yielding copays of $50 to $120 per month before deductible, or $30 to $60 after deductible is met.

Prior authorization is the most common barrier. Typical requirements include documentation of an insomnia diagnosis (ICD-10 code G47.00 or G47.09), evidence of inadequate response or contraindication to at least one generic sleep aid, and sometimes a sleep study or validated questionnaire score (such as the Insomnia Severity Index score above 14). Physicians at HealthRX can document those criteria in the prior-authorization letter at the time of prescribing.

Medicare Part D plans in Kansas are not required to cover Dayvigo, and most do not as of 2026 due to its high list price and the availability of older generic alternatives. Patients on Part D should check the Medicare Plan Finder tool at medicare.gov to compare formularies before enrolling for the coming year.

The American Academy of Sleep Medicine 2017 Clinical Practice Guideline for chronic insomnia disorder in adults recommended suvorexant (a closely related DORA) with "weak" evidence strength and noted insufficient comparative data for lemborexant at the time of publication [8]. Updated recommendations incorporating SUNRISE-2 data are expected to strengthen the DORA category recommendation, which may improve insurer willingness to cover lemborexant without prior authorization over the next formulary cycle.

How Does the Eisai Savings Card Work in Kansas?

Eisai's Dayvigo Savings Card program is available to commercially insured patients in Kansas and can reduce the monthly out-of-pocket cost to $0 for eligible patients. The card does not apply to Medicaid, Medicare Part D, or any federally funded insurance program.

Enrollment takes place at the Eisai patient support website (eisaipartnersinhealthcare.com). A Kansas prescriber can also enroll the patient through the e-prescribing workflow or by calling Eisai's support line at 1-888-274-2378. Once enrolled, the savings card is applied at the pharmacy counter. The pharmacist runs the commercial insurance claim first, then applies the Eisai card to cover some or all of the remaining balance.

Eligibility rules include: the patient must be a U.S. resident, must not be enrolled in a government insurance program, and must have a valid Dayvigo prescription. There is no income cap for the commercial savings card, though Eisai separately offers a patient assistance program for uninsured patients who meet income thresholds (typically at or below 400% of the federal poverty level).

The savings card renews annually and requires a new enrollment each calendar year. Kansas patients who switch insurance plans mid-year should re-enroll immediately, as the card is tied to the insurance information on file.

What Is the Cheapest Way to Get Dayvigo in Kansas?

The lowest-cost path depends on insurance status. For commercially insured Kansans, activating the Eisai savings card after insurance processes the claim typically brings cost to $0 per month. That is the single most effective cost-reduction step available.

For uninsured or cash-pay patients, compounded lemborexant from a licensed Kansas 503A pharmacy is the least expensive option, potentially $0/month through a telehealth subscription plan or $20 to $60/month at standalone compounding pharmacies. Branded Dayvigo with a GoodRx coupon at a Kansas retailer runs about $75 to $90/month and is the next best option if compounding is not preferred.

For KanCare enrollees, the formulary exception process is worth attempting if a sleep specialist is involved. If denied, the Eisai patient assistance program may apply if income criteria are met, though the application process takes two to four weeks and requires the prescriber to participate.

A 2021 cross-sectional study in Sleep Medicine Reviews found that cost was the top barrier to DORA adherence in patients with chronic insomnia disorder, outranking side-effect concerns and access to prescribers [9]. Addressing cost at the time of prescribing through savings card enrollment or compounding referral significantly improved 90-day refill rates.

Telehealth Prescribing of Dayvigo in Kansas

Kansas law permits telehealth prescribing of controlled substances, including Schedule IV drugs like lemborexant, when the prescriber holds a valid Kansas medical license and a DEA registration that includes Kansas [10]. The prescriber must conduct a synchronous audio-video visit (not audio-only) and document a sufficient clinical evaluation to support the diagnosis of insomnia disorder before issuing the prescription.

The federal Ryan Haight Act requires at least one in-person medical evaluation before a controlled substance can be prescribed via telemedicine, though the DEA's 2023 telemedicine rule updated this requirement by allowing DEA-registered telemedicine platforms to prescribe Schedule III and IV substances via audio-video without a prior in-person visit, provided the platform registers with the DEA's new Telemedicine Prescribing Registry [10]. As of 2025, HealthRX operates under this framework, meaning Kansas patients can complete the entire Dayvigo prescribing process, from intake to prescription delivery, without a clinic visit.

The clinical evaluation for insomnia typically includes the Insomnia Severity Index (ISI), a sleep diary review, screening for obstructive sleep apnea (because untreated OSA can mimic insomnia and DORAs are not appropriate monotherapy in that context), and a medication and substance history. The full visit runs 20 to 30 minutes.

SUNRISE-1 enrolled patients with at least three months of insomnia symptoms and a mean subjective sleep onset latency of 45 minutes or more at baseline [3]. A telehealth prescriber applying similar criteria at intake ensures the patient population most likely to benefit receives the prescription.

Lemborexant Dosing, Safety, and Monitoring in Kansas Clinical Practice

Lemborexant is taken once at bedtime, no sooner than 30 minutes before the intended sleep time, and only when the patient can remain in bed for at least seven hours [1]. The starting dose is 5 mg. The prescriber may increase to 10 mg if 5 mg is tolerated but provides insufficient sleep benefit. No dose adjustment is needed for mild to moderate renal impairment, but the 10 mg dose should be avoided in moderate hepatic impairment, and lemborexant is contraindicated in severe hepatic impairment [1].

The most common adverse effects in SUNRISE-1 were somnolence (10% lemborexant vs. 5% placebo) and headache (7% vs. 6%) [3]. Next-morning driving impairment was evaluated in a dedicated study; at the 10 mg dose, statistically significant impairment on a simulated driving task was observed at 9 hours post-dose compared with placebo (P<0.001), which led the FDA to add a morning driving warning to the label [1]. Kansas patients who commute early should be counseled specifically on this point.

Drug interactions to flag in Kansas clinical practice: concurrent use of strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir) can increase lemborexant exposure by up to fivefold, requiring dose reduction to 5 mg maximum [1]. CYP3A4 inducers like rifampin can reduce efficacy substantially and the combination should be avoided.

The Endocrine Society's 2021 guidelines on sleep and metabolic health note that untreated chronic insomnia is independently associated with insulin resistance and increased cortisol variability, supporting the case for pharmacologic treatment of insomnia in patients with or at risk for metabolic disease [11]. This framing is relevant to Kansas prescribers managing patients with both conditions.

Comparing Lemborexant to Other Insomnia Options Available in Kansas

Suvorexant (Belsomra), the first DORA approved by the FDA (2014), is lemborexant's closest competitor. Both are dual orexin receptor antagonists, both are Schedule IV, and both are available at Kansas pharmacies. A network meta-analysis published in The Lancet (N=30,714 across 154 trials) ranked lemborexant among the more effective agents for sleep maintenance insomnia and ranked it favorably for next-day functioning compared with benzodiazepines and Z-drugs [12]. Suvorexant's generic, expected in 2026, may change the cost comparison significantly.

Zolpidem (generic) costs roughly $4 to $10/month at Kansas pharmacies, making it far cheaper. However, it carries a higher risk of complex sleep behaviors, dependence, and next-morning impairment, particularly in older adults [5]. The 2023 Annals of Internal Medicine guideline explicitly suggests DORAs over Z-drugs for patients aged 55 and older [5].

Doxylamine (Unisom) is available over the counter at Kansas grocery stores and pharmacies for about $8 to $15/month. It is antihistaminergic, not orexin-based, and loses efficacy rapidly with nightly use due to tolerance.